KRAS and non-small cell lung carcinoma: An analogous reduction of cytoplasmic survivin protein and EZH2 protein expression was detected in the NCI-H23 NSCLC line, which carries mutant KRASG12C, when the KRAS-G12C-specific inhibitor (KRASi) sotorasib or KRAS siRNA was used with XPO1i or XPO1 siRNA (Extended Data Fig. 2a–d).